All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Additional Biomarkers Are Needed to Inform ADC Selection in NSCLC

November 15th 2025

Benjamin P. Levy, MD, discusses advances with ADCs in lung cancer during the 20th Annual New York Lung Cancers Symposium.

Immunotherapy Advances in SCLC Highlight Promise, Limitations, and Biomarker Needs

November 15th 2025

Christine Hann, MD, PhD, discusses how recently presented SCLC data inform treatment decision-making across the LS-SCLC and ES-SCLC settings.

The OncFive: Top Oncology Articles for the Week of 11/9

November 15th 2025

The FDA has approved ziftomenib for NPM1-positive acute myeloid leukemia, has accepted a NDA for 177Lu-edotreotide for GEP-NETs, and more.

AMT-253 Demonstrates Early Efficacy and Manageable Safety in Melanoma

November 15th 2025

AMT-253 delivered durable responses in patients with melanoma with manageable toxicity, supporting continued development.

Phase 3 Data Illuminate Advancing Roles for T-DXd and Combination Approaches in HER2+ Breast Cancer

November 14th 2025

Yuan Yuan, MD, PhD, expands on several key studies informing the current and evolving use of ADCs and dual-pathway targeting in HER2-positive breast cancer.

Post-Operative Lymphatic ctDNA Data Shows Superior Sensitivity for Detecting Residual Disease in HPV-Independent HNSCC

November 14th 2025

Post-operative lymphatic ctDNA results exceeded plasma assays in detecting residual disease and predicting recurrence in HPV-independent HNSCC.

B7-H3–Targeted ADC HN-20093 Shows Strong Efficacy, Is Still Safe at Higher Dose in R/R Sarcomas

November 14th 2025

Lu Xie, MD, discusses phase 2 efficacy and safety data with the B7-H3–targeted ADC HS-20093 in relapsed/refractory sarcomas.

Adjuvant Satri-Cel Displays Preliminary Activity in Pancreatic Ductal Adenocarcinoma

November 14th 2025

Satri-cel displayed preliminary efficacy when used as adjuvant treatment in patients with pancreatic ductal adenocarcinoma.

Researchers Develop New AI Tool That Makes Detection of Skin Cancer More Accurate

November 14th 2025

A new method enhances the ability of artificial intelligence models to detect and diagnose skin cancer in individuals with darker skin.

FDA Grants Fast Track Designation to FOG-001 for Desmoid Tumors

November 14th 2025

The FDA granted fast track designation to FOG-001 for the treatment of patients with desmoid tumors.

PSMAddition Data Support Integration of Lutetium Lu 177 Vipivotide Tetraxetan into mHSPC Management

November 14th 2025

Scott Tagawa, MD, MS, FACP, FASCO, discusses data for lutetium Lu 177 vipivotide tetraxetan in mHSPC from the PSMAddition trial.

FDA Approves New Pertuzumab Biosimilar for Select HER2+ Breast Cancer Subtypes

November 13th 2025

The FDA has approved pertuzumab-dpzb as the first interchangeable biosimilar for pertuzumab across several indications in HER2-positive breast cancer.

Exercise Boosts Recovery for Patients Receiving Stem Cell Transplant

November 13th 2025

Physical activity, from walking to strength training, helps boost recovery for patients after their stem cell transplants.

FDA Grants 510(k) Clearance to EXENT System for Multiple Myeloma Diagnosis

November 13th 2025

The FDA granted 510(k) clearance to the EXENT System to aid in the diagnosis of multiple myeloma and related disorders.

FDA Accepts NDA For 177Lu-edotreotide for GEP-NETs

November 13th 2025

The NDA seeking approval of 177Lu-edotreotide for the treatment of patients with GEP-NETs has been accepted by the FDA.

FDA Approves Ziftomenib for NPM1+ R/R Acute Myeloid Leukemia

November 13th 2025

Ziftomenib has received FDA approval for the treatment of adult patients with relapsed or refractory acute myeloid leukemia harboring an NPM1 mutation.

MB-105 Receives FDA RMAT Designation in CD5+ R/R T-Cell Lymphoma

November 13th 2025

The FDA granted RMAT designation to MB-105 for CD5-positive relapsed/refractory T-cell lymphoma.

Efforts to Leverage NaPi2b Are Renewed With Novel ADC in Ovarian Cancer

November 13th 2025

Initial activity and safety with the investigational ADC TUB-040 in ovarian cancer have renewed interest in NaPi2b as a target for ADC development.

Community Administration of Bispecific Antibodies in Myeloma Hinges on Consensus and Guidance

November 13th 2025

Experts discuss considerations surrounding the integration of bispecific antibodies in community oncology for multiple myeloma.

Ifinatamab Deruxtecan Development Continues in Phase 3 Study After Robust Results in Pretreated ES-SCLC

November 12th 2025

Based on its previously demonstrated activity and tolerability in ES-SCLC, I-DXd will be examined in the phase 3 IDeate-Lung02 trial.